Neuro3 gets rights to KCNQ2 activator development programmes from Lundbeck
09 May 2023
License out/in
Preview
Source: Pharmaceutical Technology
The activation of KCNQ2 channels is likely to offer treatment options for neurological disorders, including rare forms of epilepsy. Credit: Madrolly on Shutterstock.com.
Biotechnology company Neuro3 Therapeutics has signed an exclusive worldwide licence and option agreement with pharmaceutical firm Lundbeck to develop and commercialise clinical stage KCNQ2 activators.
Neuro3 Therapeutics will receive global licences for intellectual property that cover two clinical stage and one pre-clinical stage KCNQ2 activator programmes.
Recommended Reports
Preview
Source: Pharmaceutical Technology
ReportsComplement Factor D (C3 Convertase Activator or Adipsin or Properdin Factor D or CFD or EC 3.4.21... GlobalData
Preview
Source: Pharmaceutical Technology
ReportsGPI Anchored Wall Transfer Protein 1 (PfGWT1 or EC 2.3.) Drugs in Development by Therapy Areas an... GlobalData
View all
The company will also handle the further development of these programmes through clinical proof-of-concept (PoC).
Lundbeck will have the option to co-develop and co-commercialise these KCNQ2 activators with Neuro3 after the completion of the PoC studies.
The company also holds an option to exclusively license back the rights in some territories.
Neuro3 Therapeutics founder and CEO Zheng Li stated: “We are excited to further the development of these novel KCNQ2 activators.
“Given the critical role of KCNQ2 in maintaining brain functions and the demonstrated clinical validation of this mechanism, we look forward to evaluating the clinical benefit of these KCNQ2 activators in the treatment of various CNS diseases.”
According to the clinical findings, the KCNQ2 channel’s activation is likely to offer treatment options for other types of neurological disorders, including rare forms of epilepsy.
Lundbeck Research global head and senior vice-president Tarek Samad stated: “We are pleased to enter into this agreement with Neuro3 that allows us to assess the clinical potential of these KCNQ2 activators by leveraging Neuro3 discovery and early development expertise in the CNS diseases.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.